Paraneoplastic Syndrome in Hepatocellular Carcinoma Patients

NCT ID: NCT05846035

Last Updated: 2023-05-06

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 80 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-04-15
• Study Completion Date: 2024-04-30

Brief Summary

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world with rising incidence. Globally, there has been substantial variation in prevalence of risk factors for HCC over years, like control of viral hepatitis in developing countries but growing epidemic of fatty liver disease in developed world. Changing epidemiology of HCC is related to trends in these risk factors, Paraneoplastic syndromes (PNS) are defined as systemic, metabolic, or other distant consequences of malignancy resulting, either directly or indirectly, from production by the neoplasm of substances that gain access to the blood stream, thereby exerting their effects on distant organs or tissues There is four major HCC-associated paraneoplastic syndromes among Cirrhotic patients,i.e.hypercholesterolemia,hypoglycemia,hypercalcemia,and erythrocytosis .

Conditions

Hepatocellular Carcinoma Patients

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: CROSS_SECTIONAL

Interventions

Triphasic C.T abdomen and pelvis

for cirrhotic patients to ensure hepatocellular carcinoma

Intervention Type: DIAGNOSTIC_TEST

Other Intervention Names

alpha feto protein

Eligibility Criteria

Inclusion Criteria

• - Cirrhotic Patients with HCC.
• HCC will be diagnosed based on Alpha -feto protein (AFP) and dynamic imaging.

Exclusion Criteria

• - Patient known to have primary parathyroid disease, patients with bone metastasis or excessive use of antacids.
• Patients with secondary polycythemia (as chronic hypoxia) and patients with polycythemia rubra vera.
• Patients with acute infections or GIT bleeding.
• Patients with preexisting dyslipidemia.
• Patients with significant cholestasis.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sohag University

OTHER

Sponsor Role: lead

Responsible Party

Hala Maher Abdelhafiz

resident of Tropical department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Sohag University hospitals

Sohag, , Egypt

Site Status: RECRUITING

Countries

Egypt

Central Contacts

Hala M Abdelhafeez, Resident

Role: CONTACT

halamaher@med.sohag.edu.eg

01027319657

Amr M Zaghloul, Assistant professor

Role: CONTACT

Facility Contacts

Magdy M Amin, Professor

Role: primary

References

Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology. 2022 Jul;304(1):228-237. doi: 10.1148/radiol.212426. Epub 2022 Apr 12.

Reference Type: BACKGROUND

PMID: 35412368 (View on PubMed)

Qu Q, Wang S, Chen S, Zhou L, Rui JA. Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma. Am Surg. 2014 Feb;80(2):191-6.

Reference Type: BACKGROUND

PMID: 24480222 (View on PubMed)

Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021 Jul;12(Suppl 2):S361-S373. doi: 10.21037/jgo.2020.02.08.

Reference Type: BACKGROUND

PMID: 34422400 (View on PubMed)

Other Identifiers

Soh-Med-23-04-12MS

Identifier Type: -

Identifier Source: org_study_id